about
Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies.Serum proteome analysis in patients with rheumatoid arthritis receiving therapy with tocilizumab: an anti-interleukin-6 receptor antibodyInhibition of each module of connective tissue growth factor as a potential therapeutic target for rheumatoid arthritis.Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature.A re-evaluation of anti-NA-14 antibodies in patients with primary Sjögren's syndrome: Significant role of interferon-γ in the production of autoantibodies against NA-14.JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis.Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients.The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study.Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patientsMicroRNA-766-3p Contributes to Anti-Inflammatory Responses through the Indirect Inhibition of NF-κB SignalingRapid onset of small intestinal perforation after successful steroid treatment in eosinophilic granulomatosis with polyangiitis
P50
Q32182492-21968312-32EF-420F-A218-18D356BF963EQ37154897-AFE05BBD-746F-4968-B9FE-E8A17BE1431FQ38818408-0A05F655-F121-4940-83BF-58F11B32EED3Q39173542-99CD0949-4947-47BC-9852-F779E1E18224Q39666749-1508AB30-7ABE-440F-8C8C-9BC4EF8CB92BQ41495831-03896FF9-9E82-4B9F-A389-343655EEFEBEQ48266675-379A9F1B-008B-4314-9E1D-C225B2D241A2Q48730139-DD936D5E-0183-4199-9F70-8220E3E2F1B6Q49540804-20BF3B99-3F02-424F-AD14-99CF2720B0EEQ51362330-92132EEC-D501-4520-B867-1A5B9A229ABDQ56518629-F8F437B4-3EA3-4EB4-A480-FB70FDEFEB1AQ63379249-9D3A3A27-AB47-4AAE-9EA4-D238E4B5E4C0Q87538848-3C8B8412-BEEC-4A6B-90B5-F80FDDA95513
P50
description
researcher ORCID ID = 0000-0002-8032-7147
@en
name
Keigo Ikeda
@ast
Keigo Ikeda
@en
Keigo Ikeda
@es
Keigo Ikeda
@nl
type
label
Keigo Ikeda
@ast
Keigo Ikeda
@en
Keigo Ikeda
@es
Keigo Ikeda
@nl
prefLabel
Keigo Ikeda
@ast
Keigo Ikeda
@en
Keigo Ikeda
@es
Keigo Ikeda
@nl
P31
P496
0000-0002-8032-7147